Clinical trial · Observational
Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers
Liquid Biopsies in Esophageal Adenocarcinoma: Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers
NCT05688176CI-TRIAL-00078883recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is designed to perform a explorative search of the transcriptome to detect new circulating diagnostic sensitive and specific biomarkers in patients with Barrett's esophagus or esophageal adenocarcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Neoplasms | Esophageal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Identification of plasma biomarkers (micro RNAs) for early detection of esophageal adenocarcinoma
- timeFrame
- 4 years
- description
- Identification of micro RNAs in plasma and tissue of patients with (non-)dysplastic Barrett's esophagus and EAC that are differentially abundant, compared to healthy plasma (healthy volunteers) or healthy tissue (patient-matched healthy esophagus biopsies).
- measure
- Identification of plasma biomarkers (messenger RNAs) for early detection of esophageal adenocarcinoma
- timeFrame
- 4 years
- description
- Identification of messenger RNAs in plasma and tissue of patients with (non-)dysplastic Barrett's esophagus and EAC that are differentially abundant, compared to healthy plasma (healthy volunteers) or healthy tissue (patient-matched healthy esophagus biopsies).
- measure
- Identification of biomarkers (messenger RNAs) for therapy response prediction
- timeFrame
- 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Barrett's Esophagus with length \> 3cm OR esophageal adenocarcinoma histologically proven * Adequate mental faculty, allowing to understand the proposed treatment protocol and provide informed consent * Age over 18 years * No other concurrent malignant disease * No inclusion in other clinical trials interfering with the study protocol * No concurrent chronic systemic immune or hormone therapy, except neoadjuvant chemotherapy * Absence of any severe organ insufficiency * No pregnancy or breast feeding * Written informed consent Exclusion Criteria: * Pregnancy or breast feeding * Active bacterial, viral or fungal infection * Parenchymal liver disease (any stage cirrhosis) * High risk of bleeding during biopsy (anticoagulants, esophageal varices) * Esophageal squamous cell carcinoma * Helicobacter pylori positive at the time of biopsy sampling * Radiofrequency ablation of the oesophagus * Psychiatric pathology capable of affecting comprehension and judgement faculty
References
Publications (0)
Data not yet available
No reference posted for this study.